4.4 Article

Analysis of Epididymal Protein Synthesis and Secretion

Journal

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
Volume -, Issue 138, Pages -

Publisher

JOURNAL OF VISUALIZED EXPERIMENTS
DOI: 10.3791/58308

Keywords

Developmental Biology; Issue 138; Dynamin; epididymis; epididymosome; exosome; immunofluorescence; protein secretion; sperm; sperm maturation

Funding

  1. National Health and Medical Research Council of Australia [APP1103176]

Ask authors/readers for more resources

The mammalian epididymis generates one of the most complex intraluminal fluids of any endocrine gland in order to support the post-testicular maturation and storage of spermatozoa. Such complexity arises due to the combined secretory and absorptive activity of the lining epithelial cells. Here, we describe the techniques for the analysis of epididymal protein synthesis and secretion by focusing on the model protein family of dynamin (DNM) mechanoenzymes; large GTPases that have the potential to regulate bi-directional membrane trafficking events. For the study of protein expression in epididymal tissue, we describe robust methodology for immunofluorescence labeling of target proteins in paraffin-embedded sections and the subsequent detection of the spatial distribution of these proteins via immunofluorescence microscopy. We also describe optimized methodology for the isolation and characterization of exosome like vesicles, known as epididymosomes, which are secreted into the epididymal lumen to participate in intercellular communication with maturing sperm cells. As a complementary approach, we also describe the immunofluorescence detection of target proteins in an SV40-immortalized mouse caput epididymal epithelial (mECap18) cell line. Moreover, we discuss the utility of the mECap18 cell line as a suitable in vitro model with which to explore the regulation of epididymal secretory activity. For this purpose, we describe the culturing requirements for the maintenance of the mECap18 cell line and the use of selective pharmacological inhibition regimens that are capable of influencing their secretory protein profile. The latter are readily assessed via harvesting of conditioned culture medium, concentration of secreted proteins via trichloroacetic acid/acetone precipitation and their subsequent analysis via SDS-PAGE and immunoblotting. We contend that these combined methods are suitable for the analysis of alternative epididymal protein targets as a prelude to determining their functional role in sperm maturation and/or storage.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

Dana Messinger, Micah K. Harris, Jessica R. Cummings, Chase Thomas, Tao Yang, Stefan R. Sweha, Rinette Woo, Robert Siddaway, Martin Burkert, Stefanie Stallard, Tingting Qin, Brendan Mullan, Ruby Siada, Ramya Ravindran, Michael Niculcea, Abigail Dowling, Joshua Bradin, Kevin F. Ginn, Melissa A. H. Gener, Kathleen Dorris, Nicholas A. Vitanza, Susanne Schmidt, Jasper Spitzer, Li Jiang, Mariella G. Filbin, Xuhong Cao, Maria G. Castro, Pedro R. Lowenstein, Rajen Mody, Arul Chinnaiyan, Pierre-Yves Desprez, Sean McAllister, Matthew D. Dun, Cynthia Hawkins, Sebastian M. Waszak, Sriram Venneti, Carl Koschmann, Viveka Nand Yadav

Summary: This study found that upregulation of the protein ID1 is associated with H3K27M and ACVR1 mutations in diffuse midline gliomas (DMG). Experimental evidence shows that ID1 plays a role in tumor growth and invasion, and inhibition of ID1 with cannabidiol (CBD) can decrease invasion and growth of DMG tumors. This discovery may provide new possibilities for the treatment of DMG.

NEURO-ONCOLOGY (2023)

Article Oncology

Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Nicholas A. Vitanza, Ashley L. Wilson, Wenjun Huang, Kristy Seidel, Christopher Brown, Joshua A. Gustafson, Jason K. Yokoyama, Adam J. Johnson, Blake A. Baxter, Ryan W. Koning, Aquene N. Reid, Michael Meechan, Matthew C. Biery, Carrie Myers, Stephanie D. Rawlings-Rhea, Catherine M. Albert, Samuel R. Browd, Jason S. Hauptman, Amy Lee, Jeffrey G. Ojemann, Michael E. Berens, Matthew D. Dun, Jessica B. Foster, Erin E. Crotty, Sarah E. S. Leary, Bonnie L. Cole, Francisco A. Perez, Jason N. Wright, Rimas J. Orentas, Tony Chour, Evan W. Newell, Jeffrey R. Whiteaker, Lei Zhao, Amanda G. Paulovich, Navin Pinto, Juliane Gust, Rebecca A. Gardner, Michael C. Jensen, Julie R. Park

Summary: This study reports the first administration of repeatedly dosed intracranial B7-H3 CAR T cells for patients with DIPG, indicating tolerability, detection of CAR T cells in the CSF, elevation of CSF cytokines supporting locoregional immune activation, and the feasibility of serial mass spectrometry from both serum and CSF.

CANCER DISCOVERY (2023)

Article Biochemical Research Methods

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia

Heather C. Murray, Kasey Miller, Joshua S. Brzozowski, Richard G. S. Kahl, Nathan D. Smith, Sean J. Humphrey, Matthew D. Dun, Nicole M. Verrills

Summary: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia with a poor prognosis. Mutations in kinases, such as FLT3 and KIT, are common in AML patients and are associated with treatment resistance. This study identified DNA-PK as a potential therapeutic target in AML and demonstrated that DNA-PK inhibition sensitizes AML cells with FLT3 and KIT mutations to standard treatments. The findings suggest that targeting DNA-PK could improve the outcomes of AML patients with these mutations.

MOLECULAR & CELLULAR PROTEOMICS (2023)

Article Oncology

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities

Claire Xin Sun, Paul Daniel, Gabrielle Bradshaw, Hui Shi, Melissa Loi, Nicole Chew, Sarah Parackal, Vanessa Tsui, Yuqing Liang, Mateusz Koptyra, Shazia Adjumain, Christie Sun, Wai Chin Chong, Dasun Fernando, Caroline Drinkwater, Motahhareh Tourchi, Dilru Habarakada, Dhanya Sooraj, Diana Carvalho, Phillip B. Storm, Valerie Baubet, Leanne C. Sayles, Elisabet Fernandez, Thy Nguyen, Mia Poerksen, Anh Doan, Duncan E. Crombie, Monty Panday, Nataliya Zhukova, Matthew D. Dun, Louise E. Ludlow, Bryan Day, Brett W. Stringer, Naama Neeman, Jeffrey A. Rubens, Eric H. Raabe, Maria Vinci, Vanessa Tyrrell, Jamie I. Fletcher, Paul G. Ekert, Biljana Dumevska, David S. Ziegler, Maria Tsoli, Nur Farhana Syed Sulaiman, Amos Hong Pheng Loh, Sharon Yin Yee Low, E. Alejandro Sweet-Cordero, Michelle Monje, Adam Resnick, Chris Jones, Peter Downie, Bryan Williams, Joseph Rosenbluh, Daniel Gough, Jason E. Cain, Ron Firestein

Summary: The study establishes a pediatric cancer model resource with 261 cell lines, including 224 representing childhood tumor types. Through multi-omics analysis and genetic screening, specific treatment opportunities and biomarkers in pediatric tumor classes are identified. The findings are of great significance in improving the clinical relevance of pediatric cancer treatment.

CANCER CELL (2023)

Article Oncology

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Evangeline R. Jackson, Ryan J. Duchatel, Dilana E. Staudt, Mika L. Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, W. Samantha N. Jayasekara, Marion Le Grand, Padraic S. Kearney, Alicia M. Douglas, Izac J. Findlay, Zacary P. Germon, Holly P. McEwen, Tyrone S. Beitaki, Adjanie Patabendige, David A. Skerrett-Byrne, Brett Nixon, Nathan D. Smith, Bryan Day, Neevika Manoharan, Sumanth Nagabushan, Jordan R. Hansford, Dinisha Govender, Geoff B. McCowage, Ron Firestein, Meegan Howlett, Raelene Endersby, Nicholas G. Gottardo, Frank Alvaro, Sebastian M. Waszak, Martin R. Larsen, Yolanda Colino-Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicolas Andre, Esther Hulleman, David D. Eisenstat, Nicholas A. Vitanza, Javad Nazarian, Carl Koschmann, Sabine Mueller, Jason E. Cain, Matthew D. Dun

Summary: Diffuse midline gliomas are highly lethal childhood cancers. Palliative radiotherapy is the only established treatment with limited survival benefits. ONC201, a combination of a DRD2 antagonist and ClpP agonist, has shown promising preclinical and emerging clinical efficacy in treating diffuse intrinsic pontine gliomas. Further research is needed to understand the mechanisms of response, the impact of recurring genomic features, and the potential combination therapy with a brain penetrant PI3K/Akt inhibitor, paxalisib.

CANCER RESEARCH (2023)

Editorial Material Oncology

Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?

Nicolas Andre, Guy Buyens, Eric Bouffet, David Walker, Matthew D. Dun

LANCET ONCOLOGY (2023)

Article Developmental Biology

miR-23b-3p regulates human endometrial epithelial cell adhesion implying a role in implantation

Siena Barton, Wei Zhou, Leilani L. Santos, Ellen Menkhorst, Guannan Yang, Wan Tinn Teh, Catarina Ang, Tarana Lucky, Evdokia Dimitriadis

Summary: miR-23b-3p expression is increased in the fertile endometrium during receptivity. This study investigates its role in endometrial adhesion and its downstream targets.

REPRODUCTION (2023)

Article Biochemistry & Molecular Biology

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

Zacary P. Germon, Jonathan R. Sillar, Abdul Mannan, Ryan J. Duchatel, Dilana Staudt, Heather C. Murray, Izac J. Findlay, Evangeline R. Jackson, Holly P. McEwen, Alicia M. Douglas, Tabitha McLachlan, John E. Schjenken, David A. Skerrett-Byrne, Honggang Huang, Marcella N. Melo-Braga, Maximilian W. Plank, Frank Alvaro, Janis Chamberlain, Geoff De Iuliis, R. John Aitken, Brett Nixon, Andrew H. Wei, Anoop K. Enjeti, Yizhou Huang, Richard B. Lock, Martin R. Larsen, Heather Lee, Vijesh Vaghjiani, Jason E. Cain, Charles E. de Bock, Nicole M. Verrills, Matthew D. Dun

Summary: Mutations in FLT3 gene are common in AML patients and associated with poor prognosis. This study found that oxidative stress affects growth and proliferation signaling pathways in FLT3 mutant AML. Inhibition of NOX2, an ROS-producing complex, increased apoptosis of FLT3-mutant AML cells. In mouse models, NOX2 inhibition reduced circulating cancer cells and combined treatment with NOX2 and FLT3 inhibitors improved survival.

SCIENCE SIGNALING (2023)

Correction Biochemical Research Methods

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection (vol 19, 48, 2022)

Dilana E. Staudt, Heather C. Murray, David A. Skerrett-Byrne, Nathan D. Smith, M. Fairuz B. Jamaluddin, Richard G. S. Kahl, Ryan J. Duchatel, Zacary P. Germon, Tabitha McLachlan, Evangeline R. Jackson, Izac J. Findlay, Padraic S. Kearney, Abdul Mannan, Holly P. McEwen, Alicia M. Douglas, Brett Nixon, Nicole M. Verrills, Matthew D. Dun

CLINICAL PROTEOMICS (2023)

Review Endocrinology & Metabolism

New horizons in human sperm selection for assisted reproduction

Brett Nixon, John E. Schjenken, Nathan D. Burke, David A. Skerrett-Byrne, Hanah M. Hart, Geoffry N. De Iuliis, Jacinta H. Martin, Tessa Lord, Elizabeth G. Bromfield

Summary: Male infertility is a common issue, which affects about 50% of couples seeking assisted reproductive technologies. Traditional diagnostic methods have limitations, and there is a growing focus on assessing sperm quality to accurately predict male fertility. Recent advances in sperm biology and function have provided innovative approaches for diagnosing and treating male infertility.

FRONTIERS IN ENDOCRINOLOGY (2023)

Editorial Material Health Care Sciences & Services

National brain tumour registry: a new era of research collaboration with China

Santosh Valvi, Matthew D. Dun, Jordan R. Hansford

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Article Biochemistry & Molecular Biology

The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression

Juha Saarikettu, Saara Lehmusvaara, Marko Pesu, Ilkka Junttila, Juha Partanen, Petra Sipila, Matti Poutanen, Jie Yang, Teemu Haikarainen, Olli Silvennoinen

Summary: Snd1 is an RNA-binding protein that plays important roles in gene expression. Deletion of Snd1 in mice leads to decreased fertility, organ and body size, and reduced number of myeloid cells with decreased expression of granule protein genes. Moreover, the deletion of Snd1 affects a relatively small number of gene expressions in the spleen and liver, and reveals its function in hypoxia adaptation through negatively regulating hypoxia-related miRNAs and hypoxia-induced transcription.

FASEB BIOADVANCES (2023)

Review Oncology

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia

Sam Humphries, Danielle R. Bond, Zacary P. Germon, Simon Keely, Anoop K. Enjeti, Matthew D. Dun, Heather J. Lee

Summary: Hypoxia plays a role in influencing AML progression through interactions with DNA methylation, limiting the efficacy of hypomethylating agents within the hypoxic bone marrow. Co-treatments that promote cycling of AML cells within the bone marrow or encourage their dissociation from the bone marrow may be necessary for optimal outcomes in AML patients.

CLINICAL EPIGENETICS (2023)

Review Oncology

CAR T cell therapies for diffuse midline glioma

Bryce C. Thomas, Dilana E. Staudt, Alicia M. Douglas, Michelle Monje, Nicholas A. Vitanza, Matthew D. Dun

Summary: Diffuse midline glioma (DMG) is a fatal pediatric cancer that is difficult to treat due to its location and infiltrative nature. Current treatment options have limited effectiveness, and the tumor immune microenvironment (TIME) further reduces the response to therapy. However, chimeric antigen receptor (CAR) T cell therapy shows promise in improving outcomes for DMG patients, and strategies to overcome treatment obstacles are being explored.

TRENDS IN CANCER (2023)

No Data Available